| SC 13G/A | 2024-02-14 | Chang David D | Allogene Therapeutics, Inc. | 9,964,347 | 5.8% | EDGAR |
| SC 13G/A | 2024-02-14 | Belldegrun Arie | Allogene Therapeutics, Inc. | 9,895,903 | 5.8% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Allogene Therapeutics, Inc. | 9,030,825 | 5.4% | EDGAR |
| SC 13G/A | 2024-02-09 | FMR LLC | Allogene Therapeutics, Inc. | 25,241,499 | 15.0% | EDGAR |
| SC 13G/A | 2024-01-29 | BlackRock Inc. | Allogene Therapeutics, Inc. | 10,001,804 | 5.9% | EDGAR |
| SC 13G/A | 2024-01-23 | STATE STREET CORP | Allogene Therapeutics, Inc. | - | 1.4% | EDGAR |
| SC 13D/A | 2023-10-25 | PFIZER INC | Allogene Therapeutics, Inc. | 22,032,040 | 13.1% | EDGAR |
| SC 13G | 2023-07-10 | FMR LLC | Allogene Therapeutics, Inc. | 24,917,955 | 17.1% | EDGAR |
| SC 13G/A | 2023-02-13 | Belldegrun Arie | Allogene Therapeutics, Inc. | 8,858,861 | 6.1% | EDGAR |
| SC 13G | 2023-02-13 | Chang David D | Allogene Therapeutics, Inc. | 8,427,632 | 5.7% | EDGAR |
| SC 13G | 2023-02-09 | VANGUARD GROUP INC | Allogene Therapeutics, Inc. | 7,265,221 | 5.0% | EDGAR |
| SC 13G | 2023-02-03 | STATE STREET CORP | Allogene Therapeutics, Inc. | - | 6.4% | EDGAR |
| SC 13G | 2023-02-03 | BlackRock Inc. | Allogene Therapeutics, Inc. | 8,886,572 | 6.2% | EDGAR |
| SC 13D/A | 2022-04-07 | PFIZER INC | Allogene Therapeutics, Inc. | 22,032,040 | 15.4% | EDGAR |
| SC 13G/A | 2022-02-14 | Belldegrun Arie | Allogene Therapeutics, Inc. | 7,203,248 | 5.0% | EDGAR |
| SC 13G/A | 2022-02-14 | Seaview Trust | Allogene Therapeutics, Inc. | 7,041,120 | 4.9% | EDGAR |
| SC 13G/A | 2022-02-11 | Capital Research Global Investors | Allogene Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2022-02-11 | Capital International Investors | Allogene Therapeutics, Inc. | 1,728,252 | 1.2% | EDGAR |
| SC 13G/A | 2022-02-10 | GILEAD SCIENCES INC | Allogene Therapeutics, Inc. | 1,156,689 | 0.8% | EDGAR |
| SC 13D/A | 2022-01-18 | TPG GP A, LLC | Allogene Therapeutics, Inc. | 18,716,306 | 13.2% | EDGAR |